Skip to main content

THE NASPGHAN FOUNDATION

EIN: 76-0585072Ambler, PAZIP: 19002
H12 - Medical Research501(c)(3)

Mission

THE NASPGHAN FOUNDATION FUNDS AND SUPPORTS THE RESEARCH AND EDUCATION MISSIONS OF NASPGHAN IN ORDER TO ENHANCE THE HEALTH AND WELL-BEING OF CHILDREN WITH GASTROINTESTINAL, LIVER, PANCREAS AND NUTRITIONAL DISORDERS.

Financials

YearRevenueExpensesAssets
2023$1.8M$0$7.5M

Compensation

MARGARET STALLINGS
$50,000
$0
$0
$56,096
MENNO VERHAVE MD
$0
$0
$0
$0
ANN SCHEIMANN MD MBA
$0
$0
$0
$0
PRAVEEN GODAY MD
$0
$0
$0
$0
BENJAMIN GOLD MD FAAP FACG
$0
$0
$0
$0
JEANIE HUANG MD MPH
$0
$0
$0
$0
KAREN MURRAY MD
$0
$0
$0
$0
VICKY NG MD
$0
$0
$0
$0
PATRICIA ROBUCK PHD MPH
$0
$0
$0
$0
JOEL ROSH MD
$0
$0
$0
$0
Robert Dahms
$0
$0
$0
$0

Similar Organizations

$1.7M revenue
Same sector (H12)Very similar revenue ($1.7M vs $1.8M)Same state (Pennsylvania)Comparable compensation levels
$1.9M revenue
Similar sector (H)Very similar revenue ($1.9M vs $1.8M)Same state (Pennsylvania)Similar median compensation ($63k vs $56k)
$2.1M revenue
Same sector (H12)Similar revenue ($2.1M vs $1.8M)Same state (Pennsylvania)
$1.8M revenue
Similar sector (H)Very similar revenue ($1.8M vs $1.8M)Same state (Pennsylvania)Comparable compensation levels
KIDNEY CANCER COALITION

Philadelphia, PA

$1.1M revenue
Same sector (H12)Comparable revenue ($1.1M vs $1.8M)Same state (Pennsylvania)
$916k revenue
Same sector (H12)Comparable revenue ($916k vs $1.8M)Same state (Pennsylvania)
$2.3M revenue
Similar sector (H)Similar revenue ($2.3M vs $1.8M)Same state (Pennsylvania)Comparable compensation levelsSimilar size (9 vs 11 executives)
$936k revenue
Similar sector (H)Comparable revenue ($936k vs $1.8M)Same state (Pennsylvania)Similar median compensation ($62k vs $56k)Similar size (10 vs 11 executives)
$2.2M revenue
Similar sector (H)Similar revenue ($2.2M vs $1.8M)Same state (Pennsylvania)
HEME FOUNDATION

Walnutport, PA

$1.5M revenue
Similar sector (H)Similar revenue ($1.5M vs $1.8M)Same state (Pennsylvania)
Data from IRS Form 990 filings (2023).